A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency
Author(s)
Hemann, Michael; Liu, Chuan; Ding, Hongyu; Li, Xiaoxi; Pallasch, Christian; Hong, Liya; Guo, Dianwu; Chen, Yi; Wang, Difei; Wang, Wei; Wang, Yajie; Jiang, Hai, 1979-; ... Show more Show less![Thumbnail](/bitstream/handle/1721.1/97593/Liu-2015-DNA-HDAC.pdf.jpg?sequence=4&isAllowed=y)
DownloadLiu-2015-DNA-HDAC.pdf (1.111Mb)
PUBLISHER_CC
Publisher with Creative Commons License
Creative Commons Attribution
Terms of use
Metadata
Show full item recordAbstract
Genotoxic drugs constitute a major treatment modality for human cancers; however, cancer cells' intrinsic DNA repair capability often increases the threshold of lethality and renders these drugs ineffective. The emerging roles of HDACs in DNA repair provide new opportunities for improving traditional genotoxic drugs. Here, we report the development and characterization of CY190602, a novel bendamustine‐derived drug with significantly enhanced anticancer potency. We show that CY190602's enhanced potency can be attributed to its newly gained ability to inhibit HDACs. Using this novel DNA/HDAC dual‐targeting drug as a tool, we further explored HDAC's role in DNA repair. We found that HDAC activities are essential for the expression of several genes involved in DNA synthesis and repair, including TYMS, Tip60, CBP, EP300, and MSL1. Importantly, CY190602, the first‐in‐class example of such DNA/HDAC dual‐targeting drugs, exhibited significantly enhanced anticancer activity in vitro and in vivo. These findings provide rationales for incorporating HDAC inhibitory moieties into genotoxic drugs, so as to overcome the repair capacity of cancer cells. Systematic development of similar DNA/HDAC dual‐targeting drugs may represent a novel opportunity for improving cancer therapy.
Date issued
2015-03Department
Massachusetts Institute of Technology. Department of Biology; Koch Institute for Integrative Cancer Research at MITJournal
EMBO Molecular Medicine
Publisher
Wiley Blackwell
Citation
Liu, C., H. Ding, X. Li, C. P. Pallasch, L. Hong, D. Guo, Y. Chen, et al. “A DNA/HDAC Dual-Targeting Drug CY190602 with Significantly Enhanced Anticancer Potency.” EMBO Molecular Medicine 7, no. 4 (March 9, 2015): 438–449.
Version: Final published version
ISSN
1757-4676
1757-4684